KMPH KemPharm Inc.

2.33
-0.18  -7%
Previous Close 2.51
Open 2.49
Price To Book -0.65
Market Cap 61640970
Shares 26,455,352
Volume 204,885
Short Ratio
Av. Daily Volume 387,026

SEC filingsSee all SEC filings

  1. 8-K - Current report 181219208
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181197995
  3. 8-K - Current report 181196307
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181174022
  5. 8-K - Current report 181169803

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 complete. NDA filing due 2019.
KP511/IR 511/ER
Severe pain
Phase 1 trial completed. Further trials to commence 1H 2017, with data end of 2017. NDA filing 2018.
KP201/IR
Acute pain
Top-line data released July 9, 2018 - primary endpoint met. NDA filing due 1Q 2019.
KP415
ADHD
CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.
Apadaz (KP201/APAP)
Acute pain
Pivotal trial to be initiated late 2018 or early 2019.
KP484
ADHD

Latest News

  1. KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
  2. KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing
  3. Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th
  4. KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th
  5. What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)?
  6. Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
  7. Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
  8. KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
  9. KemPharm, Inc. Reports Third Quarter 2018 Results
  10. KemPharm to Report Third Quarter 2018 Results
  11. KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®
  12. KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting
  13. KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications
  14. KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape
  15. Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings
  16. KemPharm Announces Proposed Public Offering of Common Stock
  17. KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape
  18. KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug
  19. KemPharm Posts Positive Top-Line Results on KP415 Prodrug

SEC Filings

  1. 8-K - Current report 181219208
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181197995
  3. 8-K - Current report 181196307
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181174022
  5. 8-K - Current report 181169803
  6. D - Notice of Exempt Offering of Securities 181157936
  7. 8-K - Current report 181147026
  8. 424B5 - Prospectus [Rule 424(b)(5)] 181111235
  9. 8-K - Current report 181109467
  10. 8-K - Current report 181108562